$156.56
8.125.47%
Last update: Nov 11, 6:59 PM
Veradermics Inc
MANENYSE
Veradermics rose 314.7% from $37.75 to a 1-year high of $156.56, ahead of the S&P 500's +9.3%. Its worst day was Jul 16 (−14.4%), and its low came Feb 9 at $37.03.
Feb 4, 2026 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Veradermics closed at its lowest level of the year, 1.9% below where the year started.
−3.8% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.62 beat the $-0.66 estimate on $0.00 revenue.
−7.1% · S&P 500 −0.3%
Veradermics shares rose 14.7%, while the S&P 500 fell 0.1%.
+14.7% · S&P 500 −0.1%
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and
+47.6%, the year's best day · S&P 500 +0.2%
EPS of $-1.32 missed the $-0.79 estimate on $0.00 revenue.
−3.9% · S&P 500 −0.2%
Veradermics shares fell 14.4%, while the S&P 500 fell 0.5%.
−14.4%, the year's worst day · S&P 500 −0.5%
EPS of $-0.58 beat the $-0.63 estimate on $0.00 revenue.
−1.6% · S&P 500 −0.3%
EPS of $-0.50 beat the $-0.61 estimate on $0.00 revenue.
+3.1% · S&P 500 −0.4%
Where it ended: a 1-year high close of $156.56 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 6, 2027 (EPS est. $-0.63).
Nothing in the past 12 months.
All MANE dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MANE and SPY from Benzinga historical bars. Not investment advice.
